A nationwide 12-month observatory of automated insulin delivery shows improved glucose control, sustained adoption, and reduced acute severe events

Jean Pierre Riveline; Jean Baptiste Julla; Elisabeth Bonnemaison; Michael Joubert; Sandrine Lablanche; Agnès Sola Gazagnes; Delphine Demarsy; Didier Gouet; Pauline Schaepelynck; Chloé Amouyal; Fabienne Dalla Vale; Anne Schletzer-Mari; Sylvaine Clavel; Anne Spiteri; Catherine Campinos; Sandrine Favre; Igor Tauveron; Laurence Mathivon; Sophie Borot; Guy Fagherazzi; Marc D. Breton; Jean François Gautier; Eric Renard; Jean Pierre Riveline; Manal Al Masri-Shbat; Emmanuel Cosson; Isabela Banu; Michael Joubert; Agnès Sola Gazagnes; Gaetan Prevost; Sandrine Lablanche; Pauline Schaepelynck; Charles Thivolet; Nicolas Chevalier; Sophie Borot; Bruno Guerci; Elise Bismuth; Jacques Beltrand; Delphine Demarsy; Emmanuelle Bourrinet; Didier Gouet; Lucien Marchand; Louis Gerbaud-Morlaes; Salha Fendri; Sylvaine Clavel; René Valero; Emmanuel Sonnet; Blandine Delenne; Jean Paul Donnet; Emma Carreira; for the OB2F study group

doi:10.1111/dom.70302

A nationwide 12-month observatory of automated insulin delivery shows improved glucose control, sustained adoption, and reduced acute severe events

Jean Pierre Riveline^*
, Jean Baptiste Julla
, Elisabeth Bonnemaison
, Michael Joubert
, Sandrine Lablanche
, Agnès Sola Gazagnes
, Delphine Demarsy
, Didier Gouet
, Pauline Schaepelynck
, Chloé Amouyal
, Fabienne Dalla Vale
, Anne Schletzer-Mari
, Sylvaine Clavel
, Anne Spiteri
, Catherine Campinos
, Sandrine Favre
, Igor Tauveron
, Laurence Mathivon
, Sophie Borot
, Guy Fagherazzi

Marc D. Breton, Jean François Gautier, Eric Renard, Jean Pierre Riveline^*, Manal Al Masri-Shbat, Emmanuel Cosson, Isabela Banu, Michael Joubert, Agnès Sola Gazagnes, Gaetan Prevost, Sandrine Lablanche, Pauline Schaepelynck, Charles Thivolet, Nicolas Chevalier, Sophie Borot, Bruno Guerci, Elise Bismuth, Jacques Beltrand, Delphine Demarsy, Emmanuelle Bourrinet, Didier Gouet, Lucien Marchand, Louis Gerbaud-Morlaes, Salha Fendri, Sylvaine Clavel, René Valero, Emmanuel Sonnet, Blandine Delenne, Jean Paul Donnet, Emma Carreira, for the OB2F study group

^*Corresponding author for this work

Research output: Contribution to journal › Article › Research › peer-review

1 Citation (Scopus)

Abstract

AIMS: A nationwide observational study was conducted to assess the 12-month effectiveness of AID systems in the routine care of people with Type 1 diabetes (PwT1D).

METHODS: All PwT1D, adults, and children, who initiated AID between January 1, 2022, and December 31, 2022, were included across 79 centres. Clinical data, continuous glucose monitoring (CGM) parameters, acute severe events in the last year, and HbA1c levels were collected at AID initiation, and after 3, 6, and 12 months of AID treatment. Median values [interquartile range, IQR] and % PwT1D with acute severe events were reported. The primary outcome was the change in time in range (TIR; 3.9-10 mmol/L) after 1 year with AID.

RESULTS: A total of 2741 PwT1D were included: 44.4% male, age 38 years [29], BMI 24.5 kg/m 2 [6.7], diabetes duration 19 years [20]. AID systems were MiniMed 780G in 49.7%, Tandem Control-IQ in 49.3%, others in 1%. After 12 months, TIR increased from 58.0 [21] to 70.1% [14] while HbA1c levels decreased from 7.6 [1.2] to 7.0% [0.8]. Percent PwT1D experiencing severe hypoglycaemia (SH) decreased from 4.1 to 0.9%, and ketoacidosis from 1.2 to 0.6%. All improvements were observed after 3 months, sustained through 12 months, and statistically significant (p < 0.05). Only 2.8% of PwT1D discontinued AID.

CONCLUSIONS: Twelve months of AID use in routine care improved glucose control in PwT1D, among whom there was less experienced SH and a minor discontinuation.

Original language	English
Pages (from-to)	1179-1190
Number of pages	12
Journal	Diabetes, Obesity and Metabolism
Volume	28
Issue number	2
Early online date	24 Nov 2025
DOIs	https://doi.org/10.1111/dom.70302
Publication status	E-pub ahead of print - 24 Nov 2025

Keywords

HbA1c
automated insulin delivery
ketoacidosis
severe hypoglycaemia
time in range
type 1 diabetes

Access to Document

10.1111/dom.70302Licence: CC BY-NC-ND

Cite this

Riveline, J. P., Julla, J. B., Bonnemaison, E., Joubert, M., Lablanche, S., Gazagnes, A. S., Demarsy, D., Gouet, D., Schaepelynck, P., Amouyal, C., Vale, F. D., Schletzer-Mari, A., Clavel, S., Spiteri, A., Campinos, C., Favre, S., Tauveron, I., Mathivon, L., Borot, S., ... for the OB2F study group (2025). A nationwide 12-month observatory of automated insulin delivery shows improved glucose control, sustained adoption, and reduced acute severe events. Diabetes, Obesity and Metabolism, 28(2), 1179-1190. Advance online publication. https://doi.org/10.1111/dom.70302

@article{5180cb46ea7443988e90b698e3b871d8,

title = "A nationwide 12-month observatory of automated insulin delivery shows improved glucose control, sustained adoption, and reduced acute severe events",

abstract = "AIMS: A nationwide observational study was conducted to assess the 12-month effectiveness of AID systems in the routine care of people with Type 1 diabetes (PwT1D).METHODS: All PwT1D, adults, and children, who initiated AID between January 1, 2022, and December 31, 2022, were included across 79 centres. Clinical data, continuous glucose monitoring (CGM) parameters, acute severe events in the last year, and HbA1c levels were collected at AID initiation, and after 3, 6, and 12 months of AID treatment. Median values [interquartile range, IQR] and \% PwT1D with acute severe events were reported. The primary outcome was the change in time in range (TIR; 3.9-10 mmol/L) after 1 year with AID.RESULTS: A total of 2741 PwT1D were included: 44.4\% male, age 38 years [29], BMI 24.5 kg/m 2 [6.7], diabetes duration 19 years [20]. AID systems were MiniMed 780G in 49.7\%, Tandem Control-IQ in 49.3\%, others in 1\%. After 12 months, TIR increased from 58.0 [21] to 70.1\% [14] while HbA1c levels decreased from 7.6 [1.2] to 7.0\% [0.8]. Percent PwT1D experiencing severe hypoglycaemia (SH) decreased from 4.1 to 0.9\%, and ketoacidosis from 1.2 to 0.6\%. All improvements were observed after 3 months, sustained through 12 months, and statistically significant (p < 0.05). Only 2.8\% of PwT1D discontinued AID. CONCLUSIONS: Twelve months of AID use in routine care improved glucose control in PwT1D, among whom there was less experienced SH and a minor discontinuation.",

keywords = "HbA1c, automated insulin delivery, ketoacidosis, severe hypoglycaemia, time in range, type 1 diabetes",

author = "Riveline, \{Jean Pierre\} and Julla, \{Jean Baptiste\} and Elisabeth Bonnemaison and Michael Joubert and Sandrine Lablanche and Gazagnes, \{Agn{\`e}s Sola\} and Delphine Demarsy and Didier Gouet and Pauline Schaepelynck and Chlo{\'e} Amouyal and Vale, \{Fabienne Dalla\} and Anne Schletzer-Mari and Sylvaine Clavel and Anne Spiteri and Catherine Campinos and Sandrine Favre and Igor Tauveron and Laurence Mathivon and Sophie Borot and Guy Fagherazzi and Breton, \{Marc D.\} and Gautier, \{Jean Fran{\c c}ois\} and Eric Renard and Riveline, \{Jean Pierre\} and Masri-Shbat, \{Manal Al\} and Emmanuel Cosson and Isabela Banu and Michael Joubert and Gazagnes, \{Agn{\`e}s Sola\} and Gaetan Prevost and Sandrine Lablanche and Pauline Schaepelynck and Charles Thivolet and Nicolas Chevalier and Sophie Borot and Bruno Guerci and Elise Bismuth and Jacques Beltrand and Delphine Demarsy and Emmanuelle Bourrinet and Didier Gouet and Lucien Marchand and Louis Gerbaud-Morlaes and Salha Fendri and Sylvaine Clavel and Ren{\'e} Valero and Emmanuel Sonnet and Blandine Delenne and Donnet, \{Jean Paul\} and Emma Carreira and \{for the OB2F study group\}",

note = "Funding: OB2F has received financial support from the Soci{\'e}t{\'e} Francophone du Diab{\`e}te (SFD) {\textcopyright} 2025 The Author(s). Diabetes, Obesity and Metabolism published by John Wiley \& Sons Ltd.",

year = "2025",

month = nov,

day = "24",

doi = "10.1111/dom.70302",

language = "English",

volume = "28",

pages = "1179--1190",

journal = "Diabetes, Obesity and Metabolism",

issn = "1462-8902",

publisher = "John Wiley and Sons Inc",

number = "2",

}

Riveline, JP, Julla, JB, Bonnemaison, E, Joubert, M, Lablanche, S, Gazagnes, AS, Demarsy, D, Gouet, D, Schaepelynck, P, Amouyal, C, Vale, FD, Schletzer-Mari, A, Clavel, S, Spiteri, A, Campinos, C, Favre, S, Tauveron, I, Mathivon, L, Borot, S, Fagherazzi, G, Breton, MD, Gautier, JF, Renard, E, Riveline, JP, Masri-Shbat, MA, Cosson, E, Banu, I, Joubert, M, Gazagnes, AS, Prevost, G, Lablanche, S, Schaepelynck, P, Thivolet, C, Chevalier, N, Borot, S, Guerci, B, Bismuth, E, Beltrand, J, Demarsy, D, Bourrinet, E, Gouet, D, Marchand, L, Gerbaud-Morlaes, L, Fendri, S, Clavel, S, Valero, R, Sonnet, E, Delenne, B, Donnet, JP, Carreira, E & for the OB2F study group 2025, 'A nationwide 12-month observatory of automated insulin delivery shows improved glucose control, sustained adoption, and reduced acute severe events', Diabetes, Obesity and Metabolism, vol. 28, no. 2, pp. 1179-1190. https://doi.org/10.1111/dom.70302

A nationwide 12-month observatory of automated insulin delivery shows improved glucose control, sustained adoption, and reduced acute severe events. / Riveline, Jean Pierre; Julla, Jean Baptiste; Bonnemaison, Elisabeth et al.
In: Diabetes, Obesity and Metabolism, Vol. 28, No. 2, 24.11.2025, p. 1179-1190.

Research output: Contribution to journal › Article › Research › peer-review

TY - JOUR

T1 - A nationwide 12-month observatory of automated insulin delivery shows improved glucose control, sustained adoption, and reduced acute severe events

AU - Riveline, Jean Pierre

AU - Julla, Jean Baptiste

AU - Bonnemaison, Elisabeth

AU - Joubert, Michael

AU - Lablanche, Sandrine

AU - Gazagnes, Agnès Sola

AU - Demarsy, Delphine

AU - Gouet, Didier

AU - Schaepelynck, Pauline

AU - Amouyal, Chloé

AU - Vale, Fabienne Dalla

AU - Schletzer-Mari, Anne

AU - Clavel, Sylvaine

AU - Spiteri, Anne

AU - Campinos, Catherine

AU - Favre, Sandrine

AU - Tauveron, Igor

AU - Mathivon, Laurence

AU - Borot, Sophie

AU - Fagherazzi, Guy

AU - Breton, Marc D.

AU - Gautier, Jean François

AU - Renard, Eric

AU - Riveline, Jean Pierre

AU - Masri-Shbat, Manal Al

AU - Cosson, Emmanuel

AU - Banu, Isabela

AU - Joubert, Michael

AU - Gazagnes, Agnès Sola

AU - Prevost, Gaetan

AU - Lablanche, Sandrine

AU - Schaepelynck, Pauline

AU - Thivolet, Charles

AU - Chevalier, Nicolas

AU - Borot, Sophie

AU - Guerci, Bruno

AU - Bismuth, Elise

AU - Beltrand, Jacques

AU - Demarsy, Delphine

AU - Bourrinet, Emmanuelle

AU - Gouet, Didier

AU - Marchand, Lucien

AU - Gerbaud-Morlaes, Louis

AU - Fendri, Salha

AU - Clavel, Sylvaine

AU - Valero, René

AU - Sonnet, Emmanuel

AU - Delenne, Blandine

AU - Donnet, Jean Paul

AU - Carreira, Emma

AU - for the OB2F study group

PY - 2025/11/24

Y1 - 2025/11/24

N2 - AIMS: A nationwide observational study was conducted to assess the 12-month effectiveness of AID systems in the routine care of people with Type 1 diabetes (PwT1D).METHODS: All PwT1D, adults, and children, who initiated AID between January 1, 2022, and December 31, 2022, were included across 79 centres. Clinical data, continuous glucose monitoring (CGM) parameters, acute severe events in the last year, and HbA1c levels were collected at AID initiation, and after 3, 6, and 12 months of AID treatment. Median values [interquartile range, IQR] and % PwT1D with acute severe events were reported. The primary outcome was the change in time in range (TIR; 3.9-10 mmol/L) after 1 year with AID.RESULTS: A total of 2741 PwT1D were included: 44.4% male, age 38 years [29], BMI 24.5 kg/m 2 [6.7], diabetes duration 19 years [20]. AID systems were MiniMed 780G in 49.7%, Tandem Control-IQ in 49.3%, others in 1%. After 12 months, TIR increased from 58.0 [21] to 70.1% [14] while HbA1c levels decreased from 7.6 [1.2] to 7.0% [0.8]. Percent PwT1D experiencing severe hypoglycaemia (SH) decreased from 4.1 to 0.9%, and ketoacidosis from 1.2 to 0.6%. All improvements were observed after 3 months, sustained through 12 months, and statistically significant (p < 0.05). Only 2.8% of PwT1D discontinued AID. CONCLUSIONS: Twelve months of AID use in routine care improved glucose control in PwT1D, among whom there was less experienced SH and a minor discontinuation.

AB - AIMS: A nationwide observational study was conducted to assess the 12-month effectiveness of AID systems in the routine care of people with Type 1 diabetes (PwT1D).METHODS: All PwT1D, adults, and children, who initiated AID between January 1, 2022, and December 31, 2022, were included across 79 centres. Clinical data, continuous glucose monitoring (CGM) parameters, acute severe events in the last year, and HbA1c levels were collected at AID initiation, and after 3, 6, and 12 months of AID treatment. Median values [interquartile range, IQR] and % PwT1D with acute severe events were reported. The primary outcome was the change in time in range (TIR; 3.9-10 mmol/L) after 1 year with AID.RESULTS: A total of 2741 PwT1D were included: 44.4% male, age 38 years [29], BMI 24.5 kg/m 2 [6.7], diabetes duration 19 years [20]. AID systems were MiniMed 780G in 49.7%, Tandem Control-IQ in 49.3%, others in 1%. After 12 months, TIR increased from 58.0 [21] to 70.1% [14] while HbA1c levels decreased from 7.6 [1.2] to 7.0% [0.8]. Percent PwT1D experiencing severe hypoglycaemia (SH) decreased from 4.1 to 0.9%, and ketoacidosis from 1.2 to 0.6%. All improvements were observed after 3 months, sustained through 12 months, and statistically significant (p < 0.05). Only 2.8% of PwT1D discontinued AID. CONCLUSIONS: Twelve months of AID use in routine care improved glucose control in PwT1D, among whom there was less experienced SH and a minor discontinuation.

KW - HbA1c

KW - automated insulin delivery

KW - ketoacidosis

KW - severe hypoglycaemia

KW - time in range

KW - type 1 diabetes

UR - https://www.scopus.com/pages/publications/105025165522

UR - https://pubmed.ncbi.nlm.nih.gov/41287199/

U2 - 10.1111/dom.70302

DO - 10.1111/dom.70302

M3 - Article

C2 - 41287199

AN - SCOPUS:105025165522

SN - 1462-8902

VL - 28

SP - 1179

EP - 1190

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

IS - 2

ER -

A nationwide 12-month observatory of automated insulin delivery shows improved glucose control, sustained adoption, and reduced acute severe events

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this